Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lia Gore, Pamela Kearns, Maria Lucia Lee, Carmino Antonio De Souza, Yves Bertrand, Nobuko Hijiya, Linda C. Stork, Nack-Gyun Chung, Rocio Cardenas-Cardos, Tapan Saikia, Franca Fagioli, Jong-Jin Seo, Judith Landman-Parker, Donna Lancaster, Andrew E. Place, Karen R. Rabin, Mariana Sacchi, Rene Swanink, Michel Zwaan
Institutions: Children's Hospital Colorado, University of Colorado Anschutz, University of Birmingham, Support group for adolescents and children with cancer, Universidade Estadual de Campinas (UNICAMP), Institut d’Hématologie et d’Oncologie Pédiatrique, Lurie Children's Hospital, Oregon Health & Science University, St. Paul's Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, Instituto Nacional de Pediatria, Prince Aly Khan Hospital, Ospedale Regina Margherita, Asan Medical Center, University of Ulsan, Hôpital Armand-Trousseau, Royal Marsden Hospital, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States), Erasmus MC - Sophia Children’s Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890819543